UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 20, 2017
PixarBio Corporation |
(Name of Small Business Issuer in its Charter) |
Delaware |
| 47-1945113 |
(State or Jurisdiction of Incorporation or Organization) |
| (I.R.S. Employer Identification No.) |
200 Boston Avenue, Suite 1875
Medford, MA 02155
(Address of principal executive offices)
(617) 803-8838 |
(Telephone Number of Principal Executive Offices) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 REGULATION FD DISCLOSURE.
PixarBio Corporation (the “Company”) issued a letter to shareholders, dated March 20, 2017, providing an update on the Company.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. |
| Description |
|
|
|
| Letter to Shareholders dated March 20, 2017 – PixarBio Corporation |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PixarBio Corporation (the Company) |
| ||
| |||
Dated: March 21, 2017 | By: | /s/ Francis M. Reynolds |
|
Francis M. Reynolds |
| ||
Title: | Chief Executive Officer |
| |
3 |
